ID

19904

Beschrijving

The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.

Trefwoorden

Versies (1)
  1. 30-01-17 30-01-17 -
Geüploaded op

30 januari 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Telephone Visit CRFs Multiple Sclerosis Tysabri NCT00027300

Engels

Telephone Visit CRFs Multiple Sclerosis Tysabri NCT00027300

1 Formulieren  
Telephone Visit
Beschrijving

Telephone Visit

Alias
UMLS CUI-1
C0178941
contact not made
Beschrijving

contact not made

Datatype

boolean

Alias
UMLS CUI [1]
C1705415
date of contact
Beschrijving

date of contact

Datatype

date

Alias
UMLS CUI [1]
C0805839
Person contacted
Beschrijving

person contacted

Datatype

text

Alias
UMLS CUI [1]
C0337611
If other, specify:
Beschrijving

other person contacted

Datatype

text

Alias
UMLS CUI [1,1]
C0337611
UMLS CUI [1,2]
C3146298
Since the subject was last contacted, has the subject experienced any new or continuing adverse events? (If Yes, please record adverse event(s) in the CRF)
Beschrijving

adverse event

Datatype

boolean

Alias
UMLS CUI [1]
C0877248
Since the subject was last contacted, has the subject received any concomitant medications? (Includes IV steroid therapy and alternate MS therapy. If Yes, please record concomitant medications in the CRF)
Beschrijving

concomitant medication

Datatype

boolean

Alias
UMLS CUI [1]
C2347852
Terug naar het begin van de pagina

Similar models

Telephone Visit CRFs Multiple Sclerosis Tysabri NCT00027300

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Telephone Visit
C0178941 (UMLS CUI-1)
contact not made
Item
contact not made
boolean
C1705415 (UMLS CUI [1])
date of contact
Item
date of contact
date
C0805839 (UMLS CUI [1])
Item
Person contacted
text
C0337611 (UMLS CUI [1])
person contacted
Code List
Person contacted
CL Item
Subject (Subject)
CL Item
Other (Other)
other person contacted
Item
If other, specify:
text
C0337611 (UMLS CUI [1,1])
C3146298 (UMLS CUI [1,2])
adverse event
Item
Since the subject was last contacted, has the subject experienced any new or continuing adverse events? (If Yes, please record adverse event(s) in the CRF)
boolean
C0877248 (UMLS CUI [1])
concomitant medication
Item
Since the subject was last contacted, has the subject received any concomitant medications? (Includes IV steroid therapy and alternate MS therapy. If Yes, please record concomitant medications in the CRF)
boolean
C2347852 (UMLS CUI [1])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial